Showing posts with label Therapeutics. Show all posts
Showing posts with label Therapeutics. Show all posts
Thursday, May 29, 2025

Here is a list of cutting edge, smallcap biotech stocks we own and in order!

›
  Generative AI is transforming healthcare faster than almost any other sector, according to a new McKinsey report Here is a ranked analysis...
Thursday, February 20, 2025

In 2025, the biotechnology sector is witnessing transformative advancements, with several companies at the forefront of revolutionizing medicine

›
  Here is a very brief overview of why we are investing in these cutting edge BioTech Stocks now! Below is a comparative overview of Intelli...
Sunday, December 1, 2024

Three companies are leading the charge into Gene editing technology and medical advancements that seek to cure otherwise incurable diseases!

›
  A Comparative Analysis of Intellia Therapeutics, CRISPR Therapeutics, and Beam Therapeutics Executive Summary This report presents a compa...
Thursday, July 25, 2024

Adaptive Biotechnologies (ADPT on Nasdaq) is making significant advancements in biotechnology, focusing on harnessing the adaptive immune system for diagnosing and treating diseases

›
  One of their primary areas of development is in T-cell receptor (TCR) therapeutics. They have identified and characterized over 8,000 uniq...
Tuesday, June 25, 2024

Going forward, how viable is Beam Therapeutics in the BioTech market?

›
  Fr: ChatGPT Beam Therapeutics appears to be a viable biotechnology company, with several strengths that contribute to its potential: Finan...
Friday, May 24, 2024

Editas Medicine and CRISPR Therapeutics are both gene-editing companies that focus on developing therapies using CRISPR-Cas9 technology.

›
    Let’s explore their differences and where they stand in terms of DNA editing technology: Editas Medicine : Market Cap : Approximately $4...